Natco Pharma Limited has announced a Board Meeting scheduled for Tuesday, March 24, 2026. The primary agenda item is the consideration of a Scheme of Arrangement for the demerger of its Agrochemicals Division. This division will be spun off into its Wholly Owned Subsidiary, Natco Crop Health Sciences Limited. Concurrently, the company has enforced a trading window closure for insiders from March 19 to March 26, 2026.
Key Board Agenda Announced
Natco Pharma Limited has formally notified stock exchanges regarding an upcoming meeting of its Board of Directors. This crucial meeting is scheduled to take place on Tuesday, the 24th day of March 2026. The principal item requiring the Board’s approval is the consideration of a significant Scheme of Arrangement.
Details of the Corporate Restructuring
The proposed restructuring involves the demerger of the entire Agrochemicals Division of Natco Pharma. This division will be transferred on a going concern basis into the company’s Wholly Owned Subsidiary, which is named Natco Crop Health Sciences Limited. This strategic move aims to streamline operations and potentially unlock value within the specialized agrochemical segment.
Trading Window Closure Notice
In compliance with market regulations concerning insider trading, the company has also mandated a temporary closure of the trading window for its securities. This closure applies to all Employees, connected persons, and their immediate relatives. The period for the trading window closure commences on March 19, 2026, and will conclude on March 26, 2026 (inclusive of both dates). Subsequently, the trading window is set to reopen for normal operations on March 27, 2026.
Source: BSE
